What is NAD+ IV therapy?
NAD⁺ (nicotinamide adenine dinucleotide) is a cofactor in every metabolically active cell. It sits at the centre of the electron transport chain, drives the redox reactions that produce ATP, and serves as the substrate for the sirtuin family of enzymes — the same enzymes that have driven the last decade of longevity research.
Tissue NAD⁺ declines with age. By age 60, levels are reported to fall by roughly half in healthy populations. Chronic stress, illness, and inflammation accelerate the decline. The therapeutic question is whether restoring tissue NAD⁺ produces clinical benefit — and how to deliver it.
Why oral NAD+ supplements don't reach tissue
NAD⁺ itself is poorly absorbed orally — most is hydrolysed in the gut before reaching circulation. The supplement industry has moved to precursors: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), both of which are converted to NAD⁺ inside cells.
Bioavailability data on these precursors is contested. Some trials show modest increases in blood NAD⁺, others show no significant change. Tissue uptake — the layer that matters — is harder to measure and remains under active investigation. Even in favourable trials, the increase achieved by oral precursors is small compared with what direct IV administration produces.
What IV NAD+ delivers
IV NAD⁺ at 250–500 mg per session delivers the cofactor into circulation in its active form. Tissue uptake from circulation is direct. The effect builds across consecutive monthly doses — single sessions are useful as introductions but the metabolic adaptation requires repetition.
Why the long infusion. NAD⁺ infused too quickly causes facial flushing, chest pressure, and occasionally a vagal response with bradycardia. The 90-minute infusion at 250 mg (Anti-aging 35+) and 120-minute infusion at 500 mg (Anti-aging 55+) are documented safe rates.
Why we stop at 500 mg per session
Above 500 mg per session, the rate of side effects rises sharply while the marginal cellular uptake plateaus. Some clinics offer 750–1000 mg per session; the literature supporting that range in healthy adults is limited, and the safety margin narrows.
INFUZE's ceiling is 500 mg. Clients begin at the 250 mg Anti-aging 35+ dose, document tolerance and effect, review bloodwork, and only then move to Anti-aging 55+ at quarterly cadence. The ceiling is a clinical choice — chasing higher numbers without supporting evidence is the opposite of conservative medicine.
What you can reasonably expect
Mental clarity the evening of the session is the most-reported subjective effect. Metabolic effects — fatigue tolerance, exercise recovery — build across three to six consecutive monthly sessions. Sirtuin-mediated effects are reported in animal models; human clinical outcomes are an active research area, not settled science. We do not claim outcomes the literature doesn't support.
Common questions
- How is IV NAD+ different from NMN supplements?
- NMN is a precursor that the body converts to NAD⁺ — when it absorbs at all. IV NAD⁺ delivers the cofactor directly in its active form, at doses unachievable orally.
- Will I feel different after a single session?
- Mental clarity is the typical same-day report. Metabolic effects build across consecutive monthly sessions — single doses are not the right frame.
- Why not just 1000 mg per session?
- Above 500 mg per session, the side-effect rate rises while the marginal benefit plateaus. We chose a documented safe ceiling rather than chase a higher number.